자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapies and medications are not effective. A customized treatment may be the solution.

Cue is a digital intervention platform that translates passively acquired normal sensor data from smartphones into personalised micro-interventions to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct features that are able to change mood as time passes.

Predictors of Mood

depression treatment without drugs is one of the most prevalent causes of mental illness.1 However, only half of those suffering from the disorder receive treatment1. To improve the outcomes, clinicians need to be able to identify and treat patients who have the highest probability of responding to certain treatments.

A customized depression treatment is one way to do this. Utilizing sensors on mobile phones and an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from the treatments they receive. With two grants awarded totaling over $10 million, they will make use of these technologies to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.

So far, the majority of research on factors that predict depression treatment effectiveness has focused on clinical and sociodemographic characteristics. These include demographics such as gender, age and education as well as clinical aspects like severity of symptom and comorbidities, as well as biological markers.

A few studies have utilized longitudinal data to predict mood in individuals. A few studies also take into account the fact that moods can differ significantly between individuals. It is therefore important to develop methods that allow for the analysis and measurement of individual differences in mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can identify various patterns of behavior and emotion that are different between people.

In addition to these modalities the team also developed a machine-learning algorithm that models the dynamic variables that influence each person's mood. The algorithm combines these personal differences into a unique "digital phenotype" for each participant.

This digital phenotype was linked to CAT DI scores that are a psychometrically validated symptoms severity scale. The correlation was weak however (Pearson r = 0,08, P-value adjusted by BH 3.55 x 10 03) and varied greatly between individuals.

Predictors of symptoms

situational depression treatment is the leading cause of disability in the world, but it is often not properly diagnosed and treated. In addition the absence of effective treatments and stigma associated with depressive disorders prevent many people from seeking help.

To assist in individualized treatment, it is essential to identify predictors of symptoms. Current prediction methods rely heavily on clinical interviews, which aren't reliable and only reveal a few symptoms associated with treating depression.

Machine learning can enhance the accuracy of the diagnosis and treatment of depression by combining continuous, digital behavioral patterns gathered from sensors on smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes are able to provide a wide range of unique behaviors and activities that are difficult to capture through interviews, and allow for continuous and high-resolution measurements.

The study enrolled University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical care depending on their depression severity. Those with a CAT-DI score of 35 or 65 were allocated online support via a peer coach, while those who scored 75 patients were referred for psychotherapy in-person.

At the beginning of the interview, participants were asked an array of questions regarding their personal characteristics and psychosocial traits. The questions included age, sex, and education as well as financial status, marital status, whether they were divorced or not, the frequency of suicidal thoughts, intentions or attempts, as well as how often they drank. Participants also rated their level of depression symptom severity on a 0-100 scale using the CAT-DI. The CAT-DI assessment was conducted every two weeks for participants who received online support and weekly for those who received in-person assistance.

Predictors of the Reaction to Treatment

A customized treatment for depression is currently a top research topic, and many studies aim to identify predictors that enable clinicians to determine the most effective medications for each patient. Particularly, pharmacogenetics can identify genetic variations that affect how the body's metabolism reacts to antidepressants. This lets doctors select the medication that are most likely to work for every patient, minimizing time and effort spent on trial-and-error treatments and avoiding any side negative effects.

Another approach that is promising is to develop prediction models that combine information from clinical studies and neural imaging data. These models can be used to determine the best combination of variables that are predictive of a particular outcome, such as whether or not a particular medication is likely to improve the mood and symptoms. These models can be used to predict the response of a patient to treatment, allowing doctors maximize the effectiveness.

A new type of research uses machine learning methods, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to blend the effects of several variables to improve predictive accuracy. These models have been demonstrated to be effective in predicting private treatment for depression outcomes, such as response to antidepressants. These approaches are becoming more popular in psychiatry and will likely become the norm in the future medical practice.

In addition to prediction models based on ML The study of the underlying mechanisms of depression is continuing. Recent findings suggest that the disorder is associated with neural dysfunctions that affect specific circuits. This theory suggests that a individualized treatment for depression will be based on targeted therapies that restore normal function to these circuits.

One method of doing this is to use internet-based interventions that can provide a more individualized and tailored experience for patients. One study found that a web-based program improved symptoms and provided a better quality life for MDD patients. Additionally, a randomized controlled study of a customized approach to depression treatment showed an improvement in symptoms and fewer adverse effects in a large percentage of participants.

Predictors of Side Effects

In the treatment of depression, a major challenge is predicting and identifying the antidepressant that will cause minimal or zero adverse negative effects. Many patients are prescribed various medications before finding a medication that is both effective and well-tolerated. Pharmacogenetics offers a new and exciting method to choose antidepressant medicines that are more effective and precise.

There are a variety of variables that can be used to determine which antidepressant should be prescribed, including genetic variations, patient phenotypes such as ethnicity or gender and the presence of comorbidities. To determine the most reliable and valid predictors for a specific treatment, controlled trials that are randomized with larger samples will be required. This is because the identifying of interaction effects or moderators could be more difficult in trials that consider a single episode of treatment per patient, rather than multiple episodes of treatment over time.

In addition, predicting a patient's response will likely require information on comorbidities, symptom profiles and the patient's subjective experience of tolerability and effectiveness. Presently, only a handful of easily measurable sociodemographic and clinical variables are believed to be reliable in predicting response to MDD like gender, age, race/ethnicity and SES, BMI, the presence of alexithymia and the severity of depressive symptoms.

Many challenges remain when it comes to the use of pharmacogenetics to treat depression treatment history. First, it is essential to be able to comprehend and understand the definition of the genetic mechanisms that cause depression, as well as a clear definition of a reliable predictor of treatment response. Ethics such as privacy and the ethical use of genetic information are also important to consider. The use of pharmacogenetics may, in the long run reduce stigma associated with mental health treatments and improve the quality of treatment. However, as with all approaches to psychiatry, careful consideration and planning is essential. For now, the best option is to offer patients a variety of effective depression medications and encourage them to speak openly with their doctors about their concerns and experiences.